Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Gossamer Bio, Inc.NASDAQ: GOSS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 234.14M shares rose 3.2% year over year, ahead of the +1.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at +39.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.2% holds above the trailing-twelve-month pace of +1.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
234.14M+3.3% QoQ
Last fiscal yearDec 2025
228.52M+1.0% YoY
LTMMar 2026
229M+1.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.2%——
1 year+1.0%——
3-year CAGR+39.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
228.52M USD
Year-over-year change
+1.0%
4-year CAGR
+32.2%

Weighted Avg Shares vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 weighted avg shares of 229M shares is the 2nd highest of the 9 companies compared; the peer median is 56.66M shares.
  • Its year-over-year change of +1.1% is the 7th highest of 8, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of +39.3% compares with a peer median of +19.3%.
GOSS Competitors Peer median
Weighted Avg Shares for GOSS and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.59M +6.8%+29.9%
GOSSGossamer Bio, Inc.LTM Mar 2026229M +1.1%+39.3%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
PRTAProthena Corporation plcLTM Mar 202653.8M -0.0%+4.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202552.2M ——
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
Peer median (excluding GOSS) 56.66M+6.8%+19.3%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000114.7M48.47M
Cost of Revenue00001M
Gross Profit000114.7M47.47M
Gross Margin———100.0%97.9%
Research & Development170.27M170.92M135.3M138.49M174.09M
Selling, General & Admin45.78M47.61M38.46M36.13M37.63M
Operating Expenses216.12M218.59M183.76M174.62M210.72M
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
EBITDA(209.4M)(211.07M)(161.92M)(39.97M)(158.47M)
EBITDA Margin———-34.8%-326.9%
Operating Income(216.12M)(218.59M)(183.76M)(59.92M)(163.25M)
Operating Margin———-52.2%-336.8%
Interest Income761K1.58M2M1.78M1.97M
Interest Expense19.44M13.88M13.51M11.52M10.99M
Other Income / Expenses(17.88M)(10.79M)3.94M4.28M(7.21M)
Income Before Tax(234M)(229.38M)(179.82M)(55.64M)(170.46M)
Pre-Tax Margin———-48.5%-351.7%
Income Tax Expense000893K(88K)
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Net Margin———-49.3%-351.5%
EPS (Basic)(3.33)(2.84)(0.80)(0.25)(0.75)
EPS (Diluted)(3.33)(2.84)(1.18)(0.25)(0.75)
Weighted Avg Shares74.84M84.57M225.57M226.23M228.52M
Weighted Avg Shares (Diluted)74.84M84.57M225.57M226.23M228.52M

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.